Citigroup analyst Tyler Radke maintains Bandwidth (NASDAQ:BAND) with a Neutral and raises the price target from $17 to $19.
Equillium Announces Initiation Of Phase 2 Study Of EQ101 A First-in-Class Multi-Cytokine Inhibitor Of IL-2, IL-9 And IL-15 Targeting Alopecia Areata
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has
